Novo Nordisk CagriSema Fails vs Zepbound; Ozempic and Wegovy Prices Slashed 50%
Novo Nordisk’s candidate CagriSema failed to outperform Lilly’s Zepbound in trials, while Lilly launched a monthly-dose pen for Zepbound, bolstering its market lead. Novo Nordisk carved list-price cuts of up to 50% for Ozempic and Wegovy to boost patient access and defend market share in the global GLP-1 segment.
1. CagriSema Trial Outcome
Novo Nordisk’s obesity candidate CagriSema did not achieve superior weight loss versus Lilly’s Zepbound in head-to-head efficacy trials, which undermines its competitive positioning in the rapidly expanding GLP-1 weight loss market.
2. Ozempic and Wegovy Price Reductions
Novo Nordisk announced list-price cuts of up to 50% for its flagship GLP-1 therapies Ozempic and Wegovy, aiming to expand patient access and reinforce volume growth amid intensifying pricing pressure globally.
3. Market Implications and Outlook
The combined trial setback and deeper discounts may compress Novo’s gross margins, though increased volume could offset some revenue impact. Lilly’s new monthly-dose Zepbound pen further tightens competition, challenging Novo to innovate and defend its leadership in the obesity drug segment.